

# INTELLEWAVE

Heart Rate Variability Testing  
With Clusterization of Spectral  
Function Components

Alexander Riftine, Ph.D  
INTELLEWAVE INC.

# Intellexwave Heart Rate Variability testing with clusterization of Spectral Function Components

Alexander Riftine, Ph.D

Intellexwave HRV System is a fully automated cardiac monitoring device that provides real-time quantitative assessment of Heart Rate Variability analysis.

Intellexwave System HRV testing allows physicians to monitor physiological activity and assess the state of a patient's autonomic status through analysis of Spectral Function Components of R-R intervals Variability. On the one hand, HRV testing with Intellexwave System enables a physician to detect specific types of autonomic dysfunction linked to a multitude of clinical diagnoses. On the other hand, Intellexwave System is a tool for overall, general assessment of patient's physiology, and as a physiologic monitor it provides a comprehensive, in-depth patient evaluation, which standard medical practice is often missing. Such an ability to assess patient's physiology determines the wide range of Intellexwave system clinical applications and distinguishes it favorably from all other diagnostic devices based on analysis of Integrated low-frequency (LF) and Integrated high-frequency (HF) components.

Intellexwave System's proprietary algorithm (US Patent 7,826,892 B2) uses novel artificial intelligence techniques to provide clusterization of Integrated HF and Integrated LF components of spectral function. This unique representation of test results allows physicians to recognize up to 81 variations of the relationship between Integrated LF and Integrated HF components. For visualization of test results Intellexwave system uses Cartesian system of coordinates with high-frequency (HF) intensity on the horizontal axis and low-frequency (LF) intensity on the vertical axis.

*NOTE: The final decision about autonomic function can be made only by a physician and is based on the combined analysis of HF and LF relationships, and blood pressure data.*

The system includes Electrocardiogram and Blood pressure measuring device. A variety of data collected during the test (HRV, blood pressure and Electrocardiogram readings) enables doctors to evaluate (more accurately) patients' Autonomic Nervous System activity/status. The Intellexwave system is distinguished by its high accuracy, speed and reliability, and is very easy to operate.

An earlier version of the Intellexwave HRV System was validated with excellent results by Columbia University studies in 1998, 1999 and 2001.

## System Components

- ECG wired USB device or optionally wireless Acquisition Device.
- Automatic USB connected blood pressure-measuring device.
- Computer with integrated Bluetooth and a portable printer.
- ECG and R-R interval variability Analyzer Software

## DEVICE CONFIGURATIONS:

Intellewave system 1.5 included:


1. Lap-top computer with preinstalled software of ECG and R-R intervals variability analysis;
2. PBI QRS-card ECG device with optionally USB or Bluetooth wireless connections;
3. Fully automatic USB connected Blood Pressure device Meditech ABPM-05.




System configuration.

# Clusterization of the High and Low frequency components of HRV

by Alexander Riffine, Ph.D



Data input visualization (ECG, R-R intervals variability, Blood Pressure) during the HRV test.




In the medical field Intellewave System is used by physicians to objectively confirm or exclude cases of Cardiovascular Autonomic Neuropathy (CAN), Diabetic Autonomic Neuropathy (DAN) and other diseases or malfunctions of the Autonomic Nervous System (ANS). For example, information provided by Intellewave system gives a physician an ability to recognize cases of Beta-Blockers overdose or Risk of Sudden Cardiac Arrest. Moreover, the new version 1.5 includes Real-Time Autonomic assessment during Tilt-Table testing. Intellewave System can also monitor ANS activity by a "real-time" (up to 24 hrs) quantitative assessment of Spectral function components.

*NOTE: All clinical correlations of HRV analysis data is made by a physician only.*

Below you can find some samples of different clinical cases:


1. Example of excluding CAN Case (Cardiovascular Autonomic Neuropathy) during Valsalva maneuver combined with Deep Breathing you can see on a picture below.



Example of excluding CAN Case (Cardiovascular Autonomic Neuropathy) during Valsalva maneuver combined with Deep Breathing

**Assessment of Spectral Analysis during Orthostatic test**

9/15/2006 11:28:40 AM



HR	R(HF)	R(LF1)	R(LF2)
66	25	29	29

**Transition Period Assessment**

Min HR - 69




Max HR - 83

HR rest / HR max - 0.80  
30/15 Ratio - 0.82

HR	R(HF)	R(LF1)	R(LF2)
76	28	28	28

Supine		Upright	
BP	PP	MAP	MAP
N/A	N/A	N/A	N/A



**CONCLUSION**



**SUPINE:** HF is decreased moderately while LF activity on average level

**UPRIGHT:** HF is decreased significantly while LF is increased slightly

Orthostatic test results of the early stage of CAN or DAN cases

**Assessment of Spectral Analysis during Valsalva Maneuver combined with Deep Breathing**

9/15/2006 11:36:20 AM



HR	RI(HF)	RI(LF1)	RI(LF2)
69	24	30	30
71	28	21	28

**E/I Ratio - 1.12**


Min HR - 63

Max HR - 100

**Valsalva Ratio 1.58**

- High level (>1.7)
- Average level (1.3 - 1.7)
- Low level (<1.3)

Normal Breathing				Deep Breathing			
BP	PP	MAP		BP	PP	MAP	
140/90	50	106		145/85	60	105	




Valsalva maneuver combined with Deep Breathing, test results of the early stage of CAN or DAN cases

**Assessment of Spectral Analysis during Orthostatic test**

3/19/2007 1:19:12 PM

Electrocardiographic Rhythm Strip



HR	R(HF)	R(LF)	R(LF2)
77	30	30	30

Transition Period Assessment

Min HR - 77


HR rest / HR max - 0.94

30/15 Ratio - 0.93

Max HR - 82

HR	R(HF)	R(LF)	R(LF2)
77	29	30	30

Supine		Upright	
BP	PP	BP	PP
178/85	93	170/70	100
	MAP		MAP
	116		103





**CONCLUSION**  
 SUPINE: HF is decreased sharply while LF is increased slightly  
 UPRIGHT: HF is increased sharply while LF is decreased slightly

Orthostatic test results of the chronic stage of CAN case

*Assessment of Spectral Analysis during Valsalva Maneuver combined with Deep Breathing*

3/19/2007 1:29:01 PM

Electrocardiographic Rhythm Strip



**E/I Ratio - 1.5**

HR	R(HF)	R(LF1)	R(LF2)
77	30	30	30


Min HR - 77

**Valsalva Ratio 1.05**

- High level (>1.7)
- Average level (1.3 - 1.7)
- Low level (<1.3)

Max HR - 81


Normal Breathing				Deep Breathing			
BP	PP	MAP		BP	PP	MAP	
168/65	103	99		165/80	85	108	



Valsalva maneuver combined with Deep Breathing. Test Results of the chronic stage of CAN case

2/8/2004 11:15:47 AM

**Assessment of Spectral Analysis during Orthostatic test**



**Transition Period Assessment**

HR	R(HF)	R(LF)	R(LF2)
114	30	30	29
127	30	30	30


Min HR - 125

Max HR - 128

HR rest / HR max - 0.88

30/15 Ratio - 0.94

Supine			Upright		
BP	PP	MAP	BP	PP	MAP
170/110	60	130	190/120	70	143



**CONCLUSION**



**SUPINE:** HF is decreased sharply while LF is increased sharply

**UPRIGHT:** HF is decreased sharply while LF is increased sharply

Risk Stratification for Primary SCD Prevention - Orthostatic test

4/3/2012 10:48:00 AM

Electrocardiographic Rhythm Strip



HR	R(HF)	R(LF1)	R(LF2)
106	28	30	29

E/I Ratio - 1.5


Min HR - 89

Max HR - 118

Valsalva Ratio 1.32

- High level (>1.7)
- Average level (1.3 - 1.7)
- Low level (<1.3)


Normal Breathing				Deep Breathing			
BP	PP	MAP		BP	PP	MAP	
170/120	50	136		180/120	60	140	



Risk Stratification for Primary SCD Prevention - Valsalva maneuver combined with Deep Breathing

**Assessment of Spectral Analysis during Orthostatic test**

3/27/2012 1:20:57 PM



HR	R(HF)	R(LF)	R(LF2)
53	27	30	30

**Transition Period Assessment**

Min HR - 47


HR rest / HR max - 0.92  
30/15 Ratio - 0.91

Max HR - 58

HR	R(HF)	R(LF)	R(LF2)
55	26	29	30

Supine		
BP	PP	MAP
103/49	54	67

Upright		
BP	PP	MAP
115/45	70	68



**CONCLUSION**



**SUPINE:** HF is decreased significantly while LF is decreased significantly

**UPRIGHT:** HF is decreased significantly while LF is decreased significantly

Overdose of Beta-blockers - Orthostatic test

*Assessment of Spectral Analysis during Valsalva Maneuver combined with Deep Breathing*

3/27/2012 1:32:30 PM



**E/I Ratio - 1.13**

HR	R(HF)	R(LF1)	R(LF2)
53	23	22	28

Min HR - 48


Max HR - 57

**Valsalva Ratio 1.20**

- High level (>1.7)
- Average level (1.3 - 1.7)
- Low level (<1.3)


HR	R(HF)	R(LF1)	R(LF2)
56	15	14	7

Normal Breathing			Deep Breathing		
BP	PP	MAP	BP	PP	MAP
115/45	70	68	113/44	69	67



Overdose of Beta-blockers - Valsalva maneuver combined with Deep Breathing

**Assessment of Spectral Analysis during Orthostatic test**



**Attention! Test is not applicable!**

HR	R(HF)	R(LF1)	R(LF2)
70	9	13	19

HR	R(HF)	R(LF1)	R(LF2)
82	15	21	26


**Transition Period Assessment**

Min HR - 57

HR rest / HR max - 0.72  
30/15 Ratio - 0.79

Max HR - 95

Supine		Upright	
BP	PP	MAP	MAP
118/72	46	87	
		107/66	41
			79



HF: 1.5 LF: 1.0



**CONCLUSION**

**SUPINE:** HF is increased moderately while LF is increased slightly

**UPRIGHT:** HF is increased slightly while LF is increased slightly

**Assessment of Spectral Analysis during Valsalva Maneuver combined with Deep Breathing**

4/3/2012 3:16:29 PM



**E/I Ratio - 1.5**

HR	R(HF)	R(LF1)	R(LF2)
80	8	7	19

**Min HR - 63**

**Max HR - 103**

**Valsalva Ratio 1.62**


- High level (>1.7)
- Average level (1.3 - 1.7)
- Low level (<1.3)

BP	PP	MAP
102/66	36	78

**Normal Breathing**

BP	PP	MAP
100/65	35	76


**Deep Breathing**



Atrial Fibrillation case - Valsalva maneuver combined with Deep Breathing

**Assessment of Spectral Analysis during Orthostatic test**

3/27/2012 10:40:03 AM




**Transition Period Assessment**

HR	R(HF)	R(LF1)	R(LF2)
86	25	28	27
103	17	24	19

Min HR - 40  
Max HR - 100

HR rest / HR max - 0.87  
30/15 Ratio - 0.86

Supine			Upright		
BP	PP	MAP	BP	PP	MAP
140/76	64	97	160/82	78	108



**CONCLUSION**

**SUPINE:** HF is decreased significantly while LF is increased moderately


**UPRIGHT:** HF is decreased sharply while LF is increased significantly

Case of Chronic stage of CAN with a number of PVC's and SVT - Orthostatic test

**Assessment of Spectral Analysis during Valsalva Maneuver combined with Deep Breathing**

3/27/2012 10:50:17 AM

Electrocardiographic Rhythm Strip



HR	R(HF)	R(LF1)	R(LF2)
80	24	22	15

Min HR - 73

- - High level (>1.7)
- - Average level (1.3 - 1.7)
- - Low level (<1.3)

**E/I Ratio - 1.02**



**Valsalva Ratio 1.22**

Max HR - 89


Normal Breathing

BP	PP	MAP
160/82	78	108

Deep Breathing

BP	PP	MAP
140/72	68	94

HR	R(HF)	R(LF1)	R(LF2)
83	27	28	29



Clusterization of Total Power

Total Power

-2



Case of Chronic stage of CAN with a number of PVC's and SVT –  
Valsalva maneuver combined with Deep Breathing

# Chronotropic Incompetence case

## Orthostatic test

IntelWave


\*\*\*For Data Interpretation only, NOT A DIAGNOSIS; must be interpreted by a Physician\*\*

V G

56 y.o.

### Assessment of Spectral Analysis during Orthostatic test

3/19/2007 10:13:57 AM



HR	R(HF)	R(LF1)	R(LF2)
56	20	30	29

#### Transition Period Assessment

Min HR - 51

HR rest / HR max - 0.84  
30/15 Ratio - 0.83

Max HR - 68

HR	R(HF)	R(LF1)	R(LF2)
54	24	29	28


#### Supine

BP	PP	MAP
168/78	90	108

#### Upright

BP	PP	MAP
160/72	88	101

#### Clusterization of High and Low Frequency Components




■ - SUPINE  
■ - UPRIGHT  
○ - AVERAGE POINT  
 HF: -1.0 LF: -1.5  
 HF: -1.0 LF: -1.5

#### CONCLUSION


**SUPINE:** HF activity on average level while LF is decreased slightly

**UPRIGHT:** HF is decreased slightly while LF is decreased moderately


# Real-time Heart Rate Variability Analysis (every 2 -4 minutes)



Hourly monitor (calculation each hour)



## Orthostatic Test-to-test Trends of HRV components




## Syncope – pathophysiological development, during Tilt-table testing

The main benefit of Real-Time HRV analysis during Tilt-Table testing is to see changes

of Spectral function components immediately after tilt, because this information can help physician to see how developed pathophysiological process, or how created pathophysiological mechanisms.

Tilt-Table testing started with collection of 192 R-R intervals as base line data, after that immediately calculated first HF and LF components (displayed on a screen) and automatically started fast method of calculation HF and LF components after collections each next 6 R-R intervals. Calculation provided only by analysis of 192 R-R intervals each time shifted to the right after collection next 6 R-R intervals as


shown on picture below.



Red dot shown on a bottom graph is related with LF (SNS) changes, but Green dot is HF (PSNS) changes displayed after collection of each next 6 R-R intervals

On a final printout page, we can see 3 parts of information:

- Rhythmographic strip
- Changes of LF(SNS) AND HF(PSNS)
- Approximately each 1 min changes of Systolic and Diastolic Blood Pressure, see picture below



**Tilt-Table testing to recognize Syncope development.**

## Additional information on Heart Rate Variability Analysis for Autonomic Nervous System testing and related issues

It has been shown in numerous published articles [1,2,3] that there is a high correlation (approximately 95%) between a high-frequency spectral function of R-R intervals variability and the PSNS activity and an almost 70% correlation between the low-frequency function of R-R intervals variability and the SNS activity. The remaining 30% of low-frequency activity relate to PSNS activity and other regulatory mechanisms such as neuro-humoral, hormonal, thermoregulatory and baroreceptor mechanisms.

Thus, to recognize SNS and PSNS activity separately is very difficult and in order to create reliable, reproducible and quantitative assessments, it is essential to consider the following:

### **Method of data selection**

A majority of companies and scientific groups using HRV use the “5-minutes approach” as a method of data selection, but from the “Theory of Random Processes”, we learn that to make a statistical analysis of any random process we must take the same number of random events. This is one of the basic statements of the theory. In the case of HRV, the random event is the RR-interval. Each 5-minute set of such events consists of a

different number of RR-intervals, even if it is the same person being tested in all measurements. As a result, those using the “5-minute” method, a “time-based” approach, cannot get consistency and reproducibility for any HRV statistical analysis.

Currently, the only two other devices besides IntelWave that use the “definite number of R-R intervals” as the data selection method are “HERO” and “ANSIscope”.

### **Automatic detection of ectopic beats and artifacts to provide high quality HRV analysis**

Spectral analysis of R-R intervals is sensitive to any artifact or ectopic beat attained in the selected set of data. For instance, just one artifact in the center of the selected data segment dramatically increases the power of high frequency spectral function of R-R intervals variability making PSNS assessment completely wrong.

Most of companies who include HRV analysis in their product (all of the Holter-Monitors) provide artifact detection based on morphological analysis of ECG data which is very good for Holter application, but absolutely doesn't work for HRV assessment in some clinical cases such as - “seek sinus syndrome” and complicated arrhythmias. For HRV assessment detection of artifact can be made only based on analysis different patterns of consecutive R-R intervals. During development of its algorithm, IntelWave created >2000 patterns of relationships between consecutive R-R-intervals corresponding to different combinations of artifacts and ectopic beats. To organize the algorithm, IntelWave used well-known Artificial Intelligence techniques actually the theory of Production that resulted in the development of fully automatic and highly accurate HRV assessment, unique to Intelwave.

*NOTE: Instead of difficult automatic HF calculation in scientific literature we can find alternative solution to the problem of Autonomic assessment [5], which involves the use of two types of measurements as follows:*

1. Traditional Spectral analysis of R-R interval variability (mostly for LF assessment, which is much easier than HF calculation) and
2. Respiration measurement to locate the frequency band of parasympathetic activity.

Physiologically this approach is based on the correlation of “breathing waves”, measured as respiration frequency, with the PSNS activity. This correlation does exist during spontaneous breathing but only in absolutely healthy subjects and is useful in fields such as Air Force and Navy but completely not applicable for patients with abnormal breathing and the elderly.

In matter of fact Dr. Cohen [9] suggests to use combination of HRV and respiration as an economical way to avoid difficult automatic HF calculation.

*Method of Spectral analysis of R-R intervals variability (Fourier transform) with the most effective mathematical filter to amplify High and Low-frequency components.*

In the scientific literature we can find references on the “gold standard” in HRV analysis - the “Chronos algorithm” [1].

The IntelleWave algorithm (former name is the Nerve Express) was validated at Columbia University with excellent agreement between the Nerve-Express algorithm and the “Chronos algorithm” which contains the best method of filtering HF and LF components.

*Sophisticated graphical clusterization of the relationship between Integrated High-Frequency (HF) and Integrated Low-Frequency (LF) components of HRV*

This stage has been developed to make the method useful not only for researchers but also for practitioners [6,7].


IntelleWave has done this by developing a proprietary algorithm based on Artificial Intelligence methods, in particular the Marvin Minsky's Frame Theory.

### **Additional Advantages of Intellewave method**

Some of commercially available devices to assess CAN and DAN use just 3 very popular indices:

1. 30/15 ratio (after orthostatic intervention)
2. Valsalva Ratio (after Valsalva maneuver)
3. E/I Ratio (after Deep breathing)

30/15 Ratio. The main idea of this parameter is based on the theoretical suggestion that when a patient changes position from supine to upright, the highest heart rate will be on the 15th heart beat and the lowest heart rate will be on the 30th heart beat after the patient stands up (see Figure 1 below).




*Figure 1*

NOTE: Each vertical line on this figure is corresponding to the time interval between consecutive heart beats.

Physiology of this parameter is well-known and is described in scientific literature [8].

The transition period between supine and upright is subdivided into 2 phases as shown in Figure 2 below.



*Figure 2.*

*Figure 2*

1st phase of transition from the moment of standing up to HR (max) – minimum R-R interval is highly correlated with the adaptation reserve of the myocardium [8] and is calculated as  $HR(\text{Max})/HR(\text{supine})$  ratio.


2nd phase is theoretically a 30/15 Ratio, but practically it must be calculated as a ratio of  $HR(\text{min})/HR(\text{max})$  or  $RR(\text{max})/RR(\text{min})$ , because the possibility to match Heart Beat #15 with HR (max) and #30 with HR (min) can be just one of thousands of cases.

Therefore, if we calculate 30/15 Ratio exactly as HR on beat 30 over HR on beat 15 we will never get an accurate assessment. From a physiologic standpoint this ratio is consistent with a compensation response by the peripheral vascular system when a patient stands up. This parameter is, for example, very important for a patient with diabetic autonomic neuropathy (DAN).

*NOTE: A simple calculation of 30/15 ratio as HR (min)/ HR (max) is possible only when there is a previously completed detection of artifacts and ectopic beats in the transition period segment of R-R intervals. Intelwave solves this problem with its special approach to artifact detection during the transition period.*

## **Valsalva Ratio**

The classic response of heart rate during a Valsalva maneuver is to go up. As a result, R-R intervals become shorter and the Rhythmographic strip begins to curve downward (see Figure 3 below).



*Figure 3*

After completing a Valsalva maneuver the heart rate slows down, the R-R intervals become longer, and the curve starts to go up. Valsalva ratio here is calculated as HR (max)/HR (min). However, in about 25-35% of cases humans demonstrate an opposite response [8]. At the beginning, the heart rate slows down and later increases (see Figure 4 below).

In such cases the correct calculation will be HR (max)/HR (min1), and the wrong calculation--HR (max)/HR (min2).

This is just a short description of the most important problems related to the ANS testing based on Heart Rate Variability and Blood pressure analysis.




Figure 4

## REFERENCES

1. Malik M, Bigger JT, Camm AJ, et al. Heart Rate Variability. Standards of measurements, Physiologic interpretation, and clinical use. *European Heart Journal* 1996; 17: 354-81
2. A. Malliani, Milan, Italy. The Pattern of Sympathovagal Balance Explored in the frequency Domain. *News Physiol. Sci.*: 1999
3. F. Lombardi, Milan, Italy. Clinical applications of Present Physiological Understanding of HRV Components. *Cardiac Electrophysiology Review*, 2002.
4. Pagani M, Lombardi F, Guzzetti S et al. Power spectral analysis of heart rate and arterial Pressure variabilities as a marker of sympatho-vagal interaction in man and conscious. *Circ. Res.* 1986; 59: 178-193
5. Benhur Aysin, Elif Aysin “Effect of Respiration in Heart Rate Variability (HRV) analysis.
6. Riftine, Alexander. Clusterization of the relationship between SNS and PSNS activity by heart rate variability analysis. In proceedings of the 33rd International Congress of Electrocardiology. Cologne, Germany, July, 2006.
7. Riftine, Alexander. New quantification of the relationship between SNS and PSNS activity by Heart rate variability analysis. In proceedings of General assembly of Polish Cardiac Society – 1st Appointment. Warsaw, Poland, 2005.

8. Riftingine, Alexander. Quantitative assessment of the Autonomic Nervous system based on spectral analysis of R - R intervals variability. US Patent N 7,826,892 B2 from November 2, 2010.
9. L. I. Osadchy, "Body position and blood circulation", Medicine, 1982, Moscow.

**Intellewave, Inc.**  
238 Rockaway Ave  
2nd Floor  
Valley Stream, NY 11580  
Tel: 516 341 0307  
Fax: 516 341 0309  
[info@intellewave.net](mailto:info@intellewave.net)  
[www.intellewave.net](http://www.intellewave.net)